Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients
Gallium-68 labeled prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a novel tracer used for prostate cancer imaging. The aim of the study was to investigate the performance of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurre...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-07-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_47_18 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045333704278016 |
|---|---|
| author | Aravintho Natarajan Archi Agrawal Vedang Murthy Ganesh Bakshi Amit Joshi Nilendu Purandare Sneha Shah Ameya Puranik Venkatesh Rangarajan |
| author_facet | Aravintho Natarajan Archi Agrawal Vedang Murthy Ganesh Bakshi Amit Joshi Nilendu Purandare Sneha Shah Ameya Puranik Venkatesh Rangarajan |
| author_sort | Aravintho Natarajan |
| collection | DOAJ |
| description | Gallium-68 labeled prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a novel tracer used for prostate cancer imaging. The aim of the study was to investigate the performance of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrence (BCR) after definitive treatment. Scans of 96 consecutive patients were analyzed. Sixty-two patients received external beam radiotherapy, 34 underwent radical prostatectomy (RP), and 20 patients were on androgen deprivation therapy. Patients with prostate-specific antigen (PSA) level ≥>0.2 ng/mL following RP and PSA rise by 2 ng/mL or more above the nadir PSA following RT (Phoenix criteria) was considered as BCR, respectively. All patients underwent contrast-enhanced PET/CT after injection of 67–111 MBq Ga-68 PSMA ligand. Detection rates were correlated with serum PSA level. Detection rate for nodal metastases was compared with CT. Results of the scan were validated by using either biopsy or follow-up imaging or clinical follow-up. Seventy-four (77%) patients showed abnormal finding in Ga-68 PSMA PET/CT. The median serum PSA level of the population was 5.5 ng/ml (range 0.2–123 ng/ml). The median PSA of the positive scans was higher than that of the negative scans (6 vs. 1.7 ng/ml) and was statistically significant (P = 0.001 by Mann–Whitney U-test). In post-RP group, the detection rates were 23%, 50%, and 82% for PSA <1, 1–2, and >2 ng/ml, respectively. For post-RT, the detection was 86%, 85%, and 95% for PSA 2–5, 5.1–10, and >10 ng/ml, respectively. PSMA PET/CT revealed nodal metastases in 52 (54%) patients while CT showed pathological nodes only in 27 (28%) patients. Overall PSMA PET/CT revealed more number of nodes than CT (111 vs. 48 nodal station). PSMA PET/CT showed relapse in prostate/prostatic bed in 26 (27%) patients, nodal metastases in 50 (52%), skeletal metastases in 20 (21%), and other sites in 4 (4%) patients. Ga-68 PSMA PET/CT has high detection rate for localizing the site of recurrence in patients with biochemical failure and is superior to CT scan in the detection of nodal disease. |
| format | Article |
| id | doaj-art-5a078467c23e4e2db58ffd49ca1fcdb8 |
| institution | DOAJ |
| issn | 1450-1147 1607-3312 |
| language | English |
| publishDate | 2019-07-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | World Journal of Nuclear Medicine |
| spelling | doaj-art-5a078467c23e4e2db58ffd49ca1fcdb82025-08-20T02:54:43ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122019-07-01180324425010.4103/wjnm.WJNM_47_18Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patientsAravintho Natarajan0Archi Agrawal1Vedang Murthy2Ganesh Bakshi3Amit Joshi4Nilendu Purandare5Sneha Shah6Ameya Puranik7Venkatesh Rangarajan8Department of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Radiation Oncology, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Surgical Oncology, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaDepartment of Nuclear Medicine and Molecular Imaging, Uro-Oncology Disease Management Group, Tata Memorial Hospital, Mumbai, Maharashtra, IndiaGallium-68 labeled prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a novel tracer used for prostate cancer imaging. The aim of the study was to investigate the performance of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrence (BCR) after definitive treatment. Scans of 96 consecutive patients were analyzed. Sixty-two patients received external beam radiotherapy, 34 underwent radical prostatectomy (RP), and 20 patients were on androgen deprivation therapy. Patients with prostate-specific antigen (PSA) level ≥>0.2 ng/mL following RP and PSA rise by 2 ng/mL or more above the nadir PSA following RT (Phoenix criteria) was considered as BCR, respectively. All patients underwent contrast-enhanced PET/CT after injection of 67–111 MBq Ga-68 PSMA ligand. Detection rates were correlated with serum PSA level. Detection rate for nodal metastases was compared with CT. Results of the scan were validated by using either biopsy or follow-up imaging or clinical follow-up. Seventy-four (77%) patients showed abnormal finding in Ga-68 PSMA PET/CT. The median serum PSA level of the population was 5.5 ng/ml (range 0.2–123 ng/ml). The median PSA of the positive scans was higher than that of the negative scans (6 vs. 1.7 ng/ml) and was statistically significant (P = 0.001 by Mann–Whitney U-test). In post-RP group, the detection rates were 23%, 50%, and 82% for PSA <1, 1–2, and >2 ng/ml, respectively. For post-RT, the detection was 86%, 85%, and 95% for PSA 2–5, 5.1–10, and >10 ng/ml, respectively. PSMA PET/CT revealed nodal metastases in 52 (54%) patients while CT showed pathological nodes only in 27 (28%) patients. Overall PSMA PET/CT revealed more number of nodes than CT (111 vs. 48 nodal station). PSMA PET/CT showed relapse in prostate/prostatic bed in 26 (27%) patients, nodal metastases in 50 (52%), skeletal metastases in 20 (21%), and other sites in 4 (4%) patients. Ga-68 PSMA PET/CT has high detection rate for localizing the site of recurrence in patients with biochemical failure and is superior to CT scan in the detection of nodal disease.http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_47_18biochemical failurebiochemical recurrencegallium-68 prostate-specific membrane antigenpositron emission tomographyprostate cancer |
| spellingShingle | Aravintho Natarajan Archi Agrawal Vedang Murthy Ganesh Bakshi Amit Joshi Nilendu Purandare Sneha Shah Ameya Puranik Venkatesh Rangarajan Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients World Journal of Nuclear Medicine biochemical failure biochemical recurrence gallium-68 prostate-specific membrane antigen positron emission tomography prostate cancer |
| title | Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| title_full | Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| title_fullStr | Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| title_full_unstemmed | Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| title_short | Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| title_sort | initial experience of ga 68 prostate specific membrane antigen positron emission tomography computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients |
| topic | biochemical failure biochemical recurrence gallium-68 prostate-specific membrane antigen positron emission tomography prostate cancer |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_47_18 |
| work_keys_str_mv | AT aravinthonatarajan initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT archiagrawal initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT vedangmurthy initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT ganeshbakshi initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT amitjoshi initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT nilendupurandare initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT snehashah initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT ameyapuranik initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients AT venkateshrangarajan initialexperienceofga68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographyimaginginevaluationofbiochemicalrecurrenceinprostatecancerpatients |